Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830794 | 0.96 | CCKBR (0.38) | ALDH1A1KDM4ECCKBRHPGDTSHR | |
| SCHEMBL17830797 | 0.95 | ALDH1A1 (0.37) | ALDH1A1KDM4EP2RX3 | |
| SCHEMBL17830798 | 0.95 | MEN1 (0.37) | ALDH1A1KDM4ECCKBRMDM2P2RX3 | |
| SCHEMBL17830802 | 0.93 | MDM2 (0.34) | ALDH1A1KDM4ECCKBRMDM2P2RX3 | |
| SCHEMBL17830801 | 0.90 | HSP90AA1 (0.37) | ALDH1A1CCKBRP2RX3ALDH2ALDH3A1 | |
| SCHEMBL17830803 | 0.88 | PTPN7 (0.35) | ALDH1A1KDM4EMDM2P2RX3KMO | |
| SCHEMBL17830796 | 0.86 | ALDH1A1 (0.37) | ALDH1A1TSHRALDH2ALDH3A1KMO | |
| SCHEMBL17830793 | 0.86 | PARK7 (0.37) | ALDH1A1HPGDTSHRKMO | |
| SCHEMBL17830795 | 0.84 | ALDH1A1 (0.38) | ALDH1A1KDM4ECCKBRHPGDTSHR | |
| SCHEMBL17830800 | 0.82 | RECQL (0.36) | ALDH1A1MDM2P2RX3ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | ALDH1A1 4832/4885KDM4E 255/4885CCKBR 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.